Could a common steroid save lives in severe sepsis and lung failure?
NCT ID NCT07511582
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the steroid methylprednisolone can help critically ill patients with severe inflammation from sepsis or acute respiratory distress syndrome (ARDS). About 150 adults will receive a high dose, low dose, or placebo for up to 7 days. Researchers will measure organ function and survival over 30 days to see if the drug improves outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we optimize antibiotic dosing for children with sepsis?
- Could starting feeds sooner shield preterm babies from infection?
- Can brain waves predict thinking problems after sepsis?
- Can tailored nutrition boost recovery in the ICU?
- Can a Lung-Opening maneuver change a key injury marker in ARDS?
- Could simply sitting up ease breathing in severe lung failure?